Evercore ISI adds Intuitive Surgical stock to tactical list By Investing.com

Evercore ISI reiterated an In Line rating and $480 price target on Intuitive Surgical while adding the stock to its Tactical Outperform List ahead of earnings on April 21. The firm sees first-quarter 2026 procedure growth of about 16.5%, roughly 200bps above Street estimates, and potentially above 17% including Ion biopsy procedures. Additional positives include the Southern Europe distributor acquisition and optimism around the da Vinci 5 rollout, though the recent cybersecurity breach remains a risk.

Analysis

Into earnings, ISRG looks set up for a classic “good print, bad stock” dynamic: the bar has been reset by the year-to-date drawdown, but the real issue is whether procedure acceleration is enough to justify a premium multiple when the market is already questioning terminal growth. If management confirms a step-up in adoption from hospital capex prioritization, the first leg of upside should come from multiple repair rather than estimate revisions, because the Street will likely treat a one-quarter beat as validation of a longer upgrade cycle.

The second-order winner is less obvious: JNJ and, to a lesser extent, MDT are now part of the competitive lens because a visible robotics spend priority tends to reallocate capital away from legacy laparoscopic and other non-robotic platforms. That said, the deeper risk to ISRG is not competitive displacement this quarter; it is whether robotics becomes a more crowded procurement decision over the next 12-24 months, compressing pricing power and slowing install growth even if procedure volumes keep rising.

The cybersecurity incident is not a near-term earnings issue, but it matters for enterprise trust at exactly the wrong point in the sales cycle. In medtech, breaches rarely hit P&L immediately; the real damage shows up later through elongated hospital approvals, IT scrutiny, and slower system rollouts, especially in large IDNs. If management handles this cleanly, the stock can ignore it; if not, it becomes a multiple overhang that limits how far a positive procedure print can rerate the name.

Consensus seems to be underestimating how much of the upside is already “baked in” if the company merely confirms the current growth path. The more interesting asymmetry is that a modest beat could still produce a sharp squeeze because positioning is likely light after the drawdown, but a miss on procedures would be punished disproportionately given the stock’s rich starting valuation and the market’s sensitivity to evidence of saturation. The setup favors short-dated event convexity rather than a full-size outright long.

Key Decisions for Investors

• Long ISRG into earnings via a defined-risk call spread for the next 2-4 weeks: upside if procedure growth confirms upside surprise; downside limited if the print is merely in-line, with the key risk being a guidance hair-cut.
• Pair trade: long ISRG / short MDT over 1-3 months if robotics adoption remains the dominant capex priority; ISRG has the cleaner catalyst, while MDT is more exposed to slower innovation monetization.
• Avoid chasing the common-stock long pre-print at current levels; prefer waiting for either a post-earnings pullback on any guide uncertainty or a breakout above the recent trading range to reduce valuation risk.
• If ISRG gaps up strongly on earnings, monetize 30-50% of the move quickly: the first leg should be sentiment re-rating, but sustained upside requires evidence that the procedure beat is repeatable rather than a one-quarter pull-forward.
• For event hedging, consider short-dated put spreads on ISRG if procedural data disappoints; the stock’s valuation and crowded expectations make downside more convex than upside on a miss.